Dr.
Marion Koerper
is the Director
of the Hemophilia Treatment Center which participates in numerous industry-sponsored
clinical trials of factor concentrate products used to treat patients
with hemophilia. Current and recent clinical trials have included safety
and efficacy trials, trials of factor products treating patients undergoing
surgery, and comparison trials of patients using prophylactic vs episodic
treatment regimens.
The Hemophilia Treatment Center is participating in a nationwide CDC-sponsored
multi-year Universal Data Collection Program for people with bleeding
disorders. The goal of this project is to improve the health of people
with bleeding disorders by monitoring and developing prevention strategies
for the two major health complications of people with bleeding disorders
- bloodborne diseases and joint disease. In addition, the CDC is maintaining
a serum bank of blood collected from study participants in order to be
able to quickly investigate any new pathogens that might be spread through
blood products.
The Hemophilia Treatment Center is also participating in an NIH-sponsored
study enrolling patients with hemophilia who are Hepatitis C positive.
This study is looking at the complications associated with Hepatitis C
disease as well as developing new laboratory tests that can be used to
measure Hepatitis C infection and disease progression. Other research
questions include looking at the characteristics of persons who naturally
recover from Hepatitis C infection, the effect of Hepatitis B infection
on Hepatitis C, and human genes that are associated with resistance to
HIV and recovery from Hepatitis B and C and other conditions.
A recent completely nationwide CDC study looked at the complications
that patients with hemophilia have with implanted central lines.
 |
